Quick Answer
Edwards Lifesciences Corp reported Revenue From Contract With Customer Excluding Assessed Tax of $6.07 billion for the year ending 2025.
- Edwards Lifesciences Corp showed an increase of +11.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Edwards Lifesciences Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Edwards Lifesciences Corp's Revenue From Contract With Customer Excluding Assessed Tax has grown by 104.7%.
- Historical annual values: Fiscal year 2025: $6.07 billion | Fiscal year 2024: $5.44 billion | Fiscal year 2023: $5.01 billion | Fiscal year 2022: $4.46 billion | Fiscal year 2021: $5.23 billion | Fiscal year 2020: $4.39 billion | Fiscal year 2019: $4.35 billion | Fiscal year 2018: $3.72 billion | Fiscal year 2017: $3.44 billion | Fiscal year 2016: $2.96 billion.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: